









Patient Reported Outcomes^{1,2} Checklist

Migraine can **disrupt** many facets of daily life.
How are you **checking in**?

Consider using this to guide conversations with your patients.

	Rarely	Sometimes	Frequently	All the time
 <p>Work Activities & Productivity Migraine impacts my ability to do my job or progress in my career</p>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 <p>Home Activities, Errands, & Chores Migraine impacts my ability to complete tasks around the house</p>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 <p>Relationships & Social Activities Migraine impacts my ability to maintain relationships or spend time with loved ones</p>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 <p>Leisure Activities Migraine impacts my ability to do things I enjoy (e.g., hobbies)</p>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 <p>Concentration & Clear Thinking Migraine impacts my ability to concentrate or think clearly</p>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 <p>Tiredness or Energy Levels Migraine impacts my energy levels or makes me feel more tired than usual</p>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 <p>Physical Activity Migraine impacts my ability to move (e.g., bending, walking, moving head)</p>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
 <p>Other How else does migraine impact your daily life? Write it down in the space provided.</p>	<hr/> <hr/>			

1. Speck RM, et al. *J Patient Rep Outcomes*. 2019;3(1):39. 2. Lipton RB, et al. *Headache*. 2022;62(1):89-105

Function has emerged as a **key** consideration for **migraine prevention**

A study reports that while physicians report **disability** as one of the most **important factors** in assessing **migraine treatment needs**, they rarely ask about it, and patients often will **not bring it up**.⁴



Prior

Early clinical trials in migraine prevention with oral generics focused on evaluating **frequency, severity, & duration of attacks**¹⁻³

2000s

As **migraine-specific Quality of Life instruments were developed** and validated, their utility begins to increase⁷

2009

US Food and Drug Administration (FDA) **releases guidance for use of Patient Reported Outcomes to support labeling claims**⁸

2018

FDA approves the inclusion of health-related **Quality of Life endpoints in the labels of migraine preventive treatments**^{9,10}

American Headache Society highlights an improvement in function/reduction in disability as **one of the goals of migraine prevention**¹¹



WELL-BEING

50%

of people living with migraine feel **robbed of energy**, and **52%** report interference with their ability to **think clearly** or focus on **daily life activities** and tasks¹²



RELATIONSHIPS

1/2

feel they would be a **better partner** if they did not have headaches, and **39%** feel they would be a **better parent**¹³



CAREER

1 out of 3

report an **impact to their career**. Migraine affects their professional life (**70%**) and causes them to miss work (**60%**)¹³



HOME

85%

of those living with migraine report substantial reductions in their **ability to do household work** and chores¹⁴

1. Tfelt-Hansen P. *Acta Neurol Scand*. 1984;69:1-8. 2. Couch JR, Hassanein RS. *Arch Neurol*. 1979;36:695-699. 3. Solomon GD et al, *JAMA*. 1983;250(18):2500-2. 4. Holmes WF, et al. *Headache*. 2001;41(4):343-350. 5. Brandes JL et al, *May Clin Proc*. 2006;81(10):1311-9. 6. Tronvik E et al, *JAMA*. 2003;289(1):65-69. 7. Cole JC et al, *Qual Life Res*. 2007;16(7):1231-7; 8. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Accessed 3/2023: <https://www.fda.gov/media/77832/download>

9. AIMOVIG® Prescribing Information; 10. EMGALITY® Prescribing Information; 11. AHS Consensus Statement. *Headache*. 2019;59(1):1-18. 12. Data from My Migraine Voice survey: an online, global survey of people living with migraine (N=11,266) Martelletti P, et al. *J Headache Pain*. 2018;19(1):115. 13. Data from CaMEO: Chronic Migraine Epidemiology and Outcomes Study, a prospective, longitudinal, Web-based survey study of people in the U.S. living with migraine (N=8,127 for partner analysis and N=5,992 for parent analysis). Buse DC, et al. *Headache*. 2019;59(8):1286-1299. 14 Data from a computer-assisted telephone interview survey of people in the US (N=568) and UK (N=574) living with migraine. Lipton RB et al. *Cephalalgia*. 2003;23:429-440.